7-methoxy-1-(3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione | 1401683-55-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-methoxy-1-(3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione
• 英文别名: 7-Methoxy-1-[[3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione
• CAS: 1401683-55-3
• 化学式: C₂₅H₂₄N₆O₄
• 分子量: 472.503
• InChiKey: MULKWDPPVKZLCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF<br/>[FR] 1-(ARYLMÉTHYL)QUINAZOLINE-2,4(1H,3H)-DIONES EN TANT QU'INHIBITEURS DE PARP ET UTILISATION DE CELLES-CI
  申请人：IMPACT THERAPEUTICS INC

  公开号：WO2012130166A1

  公开（公告）日：2012-10-04

  Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

  公开了其1-(芳基甲基)喹唑啉-2,4(1H,3H)-二酮，其由式(I)所表示，其中Ar，R1-R6在此定义。具有式(I)的化合物是PARP抑制剂。因此，本发明的化合物可用于治疗对PARP活性抑制敏感的临床状况。
• 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof
  申请人：Cai Sui Xiong

  公开号：US20140023642A1

  公开（公告）日：2014-01-23

  Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R 1 -R 6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

  公开的是其1-(芳基甲基)喹唑啉-2,4(1H,3H)-二酮，由式(I)所代表，其中Ar，R1-R6在此定义。具有式(I)的化合物为PARP抑制剂。因此，本发明的化合物可用于治疗对PARP活性抑制有响应的临床病况。
• 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof
  申请人：Impact Therapeutics, Inc.

  公开号：US20160237070A1

  公开（公告）日：2016-08-18

  Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R 1 -R 6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

  本发明涉及一种由式（I）表示的1-(芳基甲基)喹唑啉-2,4(1H,3H)-二酮，其中Ar，R1-R6如本文所定义。具有式（I）的化合物是PARP抑制剂。因此，本发明的化合物可以用于治疗对PARP活性抑制有反应的临床病症。
• 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
  申请人：IMPACT Therapeutics, Inc.

  公开号：US10316027B2

  公开（公告）日：2019-06-11

  Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6, are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

  本发明公开了由式 (I) 代表的 1-(芳基甲基)喹唑啉-2,4(1H,3H)-二酮： 其中 Ar、R1-R6 在本文中定义。具有式（I）的化合物是 PARP 抑制剂。因此，本发明的化合物可用于治疗对抑制 PARP 活性有反应的临床病症。
• 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF
  申请人：Impact Therapeutics, Inc.

  公开号：EP2709990A1

  公开（公告）日：2014-03-26